Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers.

Bock AM, Hao P, Xu Y, Luttwak E, Thiruvengadam SK, Sekaran K, Sano D, Vaughn J, Sharp J, Major A, Patel V, Smilnak G, Araujo N, Mynam R, Reef D, Palmeri M, Gerber D, Abhyankar A, Baek G, Falade A, Iqbal M, Hu B, Geethakumari PR, Durani U, Di M, Niu A, Cherng HJ, Rhodes JM, Grover N, Pophali P, Feldman T, Shanmugasundaram K, Svoboda J, Voorhees T, Diefenbach C, Karimi Y, Karmali R, Herrera AF, Torka P, Epperla N

Open source

DOI: 10.1002/hem3.70346
Published: 2026 Apr
Container: HemaSphere
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/hem3.70346,
  title = {Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers.},
  author = {Bock AM and Hao P and Xu Y and Luttwak E and Thiruvengadam SK and Sekaran K and Sano D and Vaughn J and Sharp J and Major A and Patel V and Smilnak G and Araujo N and Mynam R and Reef D and Palmeri M and Gerber D and Abhyankar A and Baek G and Falade A and Iqbal M and Hu B and Geethakumari PR and Durani U and Di M and Niu A and Cherng HJ and Rhodes JM and Grover N and Pophali P and Feldman T and Shanmugasundaram K and Svoboda J and Voorhees T and Diefenbach C and Karimi Y and Karmali R and Herrera AF and Torka P and Epperla N},
  year = {2026},
  journal = {HemaSphere},
  doi = {10.1002/hem3.70346},
  url = {https://doi.org/10.1002/hem3.70346}
}

RIS

TY  - JOUR
TI  - Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers.
AU  - Bock AM
AU  - Hao P
AU  - Xu Y
AU  - Luttwak E
AU  - Thiruvengadam SK
AU  - Sekaran K
AU  - Sano D
AU  - Vaughn J
AU  - Sharp J
AU  - Major A
AU  - Patel V
AU  - Smilnak G
AU  - Araujo N
AU  - Mynam R
AU  - Reef D
AU  - Palmeri M
AU  - Gerber D
AU  - Abhyankar A
AU  - Baek G
AU  - Falade A
AU  - Iqbal M
AU  - Hu B
AU  - Geethakumari PR
AU  - Durani U
AU  - Di M
AU  - Niu A
AU  - Cherng HJ
AU  - Rhodes JM
AU  - Grover N
AU  - Pophali P
AU  - Feldman T
AU  - Shanmugasundaram K
AU  - Svoboda J
AU  - Voorhees T
AU  - Diefenbach C
AU  - Karimi Y
AU  - Karmali R
AU  - Herrera AF
AU  - Torka P
AU  - Epperla N
PY  - 2026
JO  - HemaSphere
DO  - 10.1002/hem3.70346
UR  - https://doi.org/10.1002/hem3.70346
ER  -

APA

AM, B., P, H., Y, X., E, L., SK, T., K, S., D, S., J, V., J, S., A, M., V, P., G, S., N, A., R, M., D, R., M, P., D, G., A, A., G, B., A, F., M, I., B, H., PR, G., U, D., M, D., A, N., HJ, C., JM, R., N, G., P, P., T, F., K, S., J, S., T, V., C, D., Y, K., R, K., AF, H., P, T., & N, E. (2026). Nivolumab in combination with AVD as frontline treatment for patients with classic Hodgkin lymphoma: A real-world analysis from 20 US centers.. HemaSphere. https://doi.org/10.1002/hem3.70346

Source records

pubmed · retrieved 2026-09-26T23:51:11.318Z